REFERENCES

1. Thackar R. Female sexual dysfunction is an artificial concept driven by commercial interests: against: FSD is a real and complex problem. BJOG 2015;122:1419.

2. Bruni C, Raja J, Denton CP, Matucci-Cerinic M.

3. Wallwiener CW, Wallwiener LM, Seeger H, et al. Are hormonal components of oral contraceptives associated with impaired female sexual function? A questionnaire-based online survey of medical students in Germany, Austria, and Switzerland. Arch Gynecol Obstet 2015;292:883-90.

4. Khajehei M, Doherty M, Tilley PJ. An update on sexual function and dysfunction in women. Arch Womens Ment Health 2015;18:423-33.

5. Latif EF, Diamond MP. Arriving at the diagnosis of female sexual dysfunction. Fertil Steril 2013;100:898-904.

6. Ozaki Y, Nagao K, Saigo R, et al. Sexual problems among Japanese women: data from an online helpline. Sex Med 2015 3;3:295-301.

7. Kingsberg SA, Woodard T. Female sexual dysfunction: focus on low desire. Obstet Gynecol 2015;125:477-86.

8. Cappelletti M, Wallen K. Increasing women’s sexual desire: the comparative effectiveness of estrogens and androgens. Horm Behav 2016;78:178-93.

9. Nappi RE, Cucinella L. Advances in pharmacotherapy for treating female sexual dysfunction. Expert Opin Pharmacother 2015;16:875-87.

10. Masters WH, Johnson VE (eds). Human Sexual Inadequacy. Boston, MA: Little Brown; 1970.

11. Kaplan HS (ed). The New Sex Therapy. New York: Brunner/ Mazel; 1974.

12. Basson R. The female sexual response: a different model. J Sex Marital Ther 2000;26:51-65.

13. Worsley R, Santoro N, Miller KK, Parish SJ, Davis SR. Hormones and female sexual dysfunction: beyond estrogens and androgens- findings from the fourth International consultation on sexual medicine. J Sex Med 2016;13:283-90.

14. Bakker J, Brock O. Early oestrogens in shaping reproductive net­works: evidence for a potential organisational role of oestradiol in female brain development. JNeuroendocrinol 2010;22: 728-35.

15. Salonia A, Giraldi A, Chivers ML, et al. Physiology of women’s sexual function: basic knowledge and new findings. J Sex Med 2010;7:2637-660.

16. Graziottin A, Gambini D. Anatomy and physiology of genital or­gans—women. Handb Clin Neurol 2015;130:39-60.

17. Komisaruk BR, Whipple B. Functional MRI of the brain during orgasm in women. Annu Rev Sex Res 2005;16:62-86.

18. Johannes CB, Clayton AH, Odom DM, et al. Distressing sexual problems in United States women revisited: prevalence after ac­counting for depression. J Clin Psychiatry 2009;70:1698-706.

19. Mitchell KR, Mercer CH, Ploubidis GB, et al. Sexual function in Britain: findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). Lancet 2013;382:1817-29.

20. Valadares AL, Lui-Filho JF, Costa-Paiva L, Pinto-Neto AM. Middle-aged female sexual dysfunction and multimorbidity: a population-based study. Menopause 2016;23:304-10.

21. Faubion SS, Rullo JE. Sexual dysfunction in women: a practical approach. Am Fam Physician 2015;92:281-88.

22. Meston CM, Levin RJ, Sipski ML, Hull EM, Heiman JR. Women’s orgasm. Annu Rev Sex Res 2004;15:173-257.

23. Pyke RE, Clayton A. Models vs. Realities in female sexual dys­function. J Sex Med 2015;12:1977-78.

24. Portman DJ, Gass ML, Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of meno­pause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. J Sex Med 2014;11:2865-72.

25. Wright JJ, O’Connor KM. Female sexual dysfunction. Med Clin North Am 2015;99:607-28.

26. Boerner KE, Rosen NO. Acceptance of vulvovaginal pain in women with provoked vestibulodynia and their partners: associ­ations with pain, psychological, and sexual adjustment.

27. Wallwiener CW, Wallwiener LM, Seeger H, Muck AO, Bitzer J, Wallwiener M. Prevalence of sexual dysfunction and impact of contraception in female German medical students. J Sex Med 2010;7:2139-48.

28. Panzer C, Wise S, Fantini G, et al. Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retro­spective study in women with sexual dysfunction. J Sex Med 2006;3:104-13.

29. Andreucci CB, Bussadori JC, Pacagnella RC, et al. Sexual life and dysfunction after maternal morbidity: a systematic review. BMC Pregnancy Childbirth 2015;15:307.

30. Fehniger JE, Brown JS, Creasman JM, et al. Childbirth and female sexual function later in life. Obstet Gynecol 2013;122:988-97.

31. Lindau ST, Coady D, Kushner D. Female sexual dysfunction: focus on low desire. Obstet Gynecol 2015;125:1495-96.

32. Stephenson KR, Meston CM. Differentiating components of sexual well-being in women: are sexual satisfaction and sexual distress independent constructs? J Sex Med 2010;7:2458-68. [Erratum in: J Sex Med 2010;7:3803.]

33. Boswell EN, Dizon DS. Breast cancer and sexual function. Transl Androl Urol 2015;4:160-68.

34. Jensen PT, Froeding LP. Pelvic radiotherapy and sexual function in women. Transl Androl Urol 2015;4:186-205.

35. Bjerggaard M, Charles M, Kristensen E, Lauritzen T, Sandbsk A, Giraldi A. Prevalence of sexual concerns and sexual dysfunction among sexually active and inactive men and women with screen- detected Type 2 diabetes. Sex Med 2015;3:302-10.

36. Rosen RC, Heiman JR, Long JS, Fisher WA, Sand MS. Men with sexual problems and their partners: findings from the International survey of relationships. Arch Sex Behav 2016;45:159-73.

37. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther 2005;31:1-20.

38. Basson R. Pharmacotherapy for women’s sexual dysfunction. Expert Opin Pharmacother 2009;10:1631-48.

39. Santoro N, Worsley R, Miller KK, Parish SJ, Davis SR. Role of estrogens and estrogen-like compounds in female sexual function and dysfunction. J Sex Med 2016;13:305-16.

40. Constantine G, Graham S, Portman DJ, Rosen RC, Kingsberg SA. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results ofa randomized, placebo-controlled trial. Climacteric 2015;18:226-32.

41. Palacios S, Mejias A. An update on drugs for the treatment ofmeno- pausal symptoms. Expert Opin Pharmacother 2015;16:2437-47.

42. Labrie F, Archer DF, Koltun W, et al. Efficacy of Intravaginal de­hydroepiandrosterone (DHEA) on moderate to severe dyspar- eunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 2016;23:243-56.

43. Belkin ZR, Krapf JM, Goldstein AT. Drugs in early clinical de­velopment for the treatment of female sexual dysfunction. Expert Opin Investig Drugs 2015;24:159-67.

44. Robinson K, Cutler JB, Carris NW. First pharmacological therapy for hypoactive sexual desire disorder in premenopausal women: flibanserin. Ann Pharmacother 2016;50:125-32.

45. Mullard A. FDA approves female sexual dysfunction drug. Nat Rev DrugDiscov 2015;14:669.

46. Dhanuka I, Simon JA. Flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women. Expert Opin Pharmacother 2015;16:2523-29.

47. Kingsberg SA, Clayton AH, Pfaus JG. The female sexual re­sponse: current models, neurobiological underpinnings and agents currently approved or under investigation for the treatment of hypoactive sexual desire disorder. CNS Drugs 2015;29:915-33.

CHAPTER 60 Female sexual dysfunction

48. Gao L, Yang L, Qian S, Li T, Han P, Yuan J. Systematic review and meta-analysis of phosphodiesterase type 5 inhibitors for the treatment of female sexual dysfunction. Int J Gynaecol Obstet 2016;133:139-45.

49. Adaikan PG, Srilatha B, Wheat AJ. Efficacy ofred clover isoflavones in the menopausal rabbit model. Fertil Steril 2009;92:2008-13.

50. Swanson CL, Rueter JA, Olson JE, Weaver AL, Stanhope CR. Localized provoked vestibulodynia: outcomes after modified vestibulectomy. J Reprod Med 2014;59:121-26.

51. Srilatha B, Huang Z, Adaikan PG. Sexual activity in midlife women and beyond. JAMA Intern Med 2014;174:1204-205.